1. Home
  2. BAOS vs LEXX Comparison

BAOS vs LEXX Comparison

Compare BAOS & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Baosheng Media Group Holdings

BAOS

Baosheng Media Group Holdings

N/A

Current Price

$0.24

Market Cap

9.1M

ML Signal

N/A

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

N/A

Current Price

$3.19

Market Cap

8.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BAOS
LEXX
Founded
2018
2004
Country
China
Canada
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1M
8.7M
IPO Year
2020
2011

Fundamental Metrics

Financial Performance
Metric
BAOS
LEXX
Price
$0.24
$3.19
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 4.6M
82.6K
Earning Date
04-30-2026
07-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $705,923.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$6,915.00
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 52.05
52 Week Low
$0.23
$0.35
52 Week High
$5.21
$14.37

Technical Indicators

Market Signals
Indicator
BAOS
LEXX
Relative Strength Index (RSI) 29.04 35.47
Support Level N/A $0.57
Resistance Level $0.36 $12.89
Average True Range (ATR) 0.03 0.51
MACD 0.03 -0.12
Stochastic Oscillator 14.75 25.92

Price Performance

Historical Comparison
BAOS
LEXX

About BAOS Baosheng Media Group Holdings

Baosheng Media Group Holdings Ltd is a China-based online marketing solution provider. The company provides internet marketing, short-video and V-log marketing, content production and operation, e-commerce marketing, data platform services, and AI technology-related services. It also offers customized marketing solutions and channel marketing services through partnerships with internet platforms such as Tencent, Alibaba, ByteDance, and Kuaishou.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: